BMY-28121, a new antitumor antibiotic
AssigneeBristol-Myers Company
InventorsMitsuaki Tsunakawa, Masataka Konishi, Takeo Miyaki
Life of this patent
Estimating the term…
Abstract
A new antitumor antibiotic designated herein as BMY-28121 is produced by fermentation of Streptomyces albus strain K731-113 (ATCC 39897). BMY-28121, which may be recovered from the fermentation broth in either its natural free hydroxy form (BMY-28121A) or methyl ether form (BMY-28121B), inhibits gram-positive bacteria and anaerobes and inhibits the growth of mammalian tumors such as P-388 leukemia, L-1210 leukemia and B16 melanoma.
Claims10
The antibiotic BMY-28121A of the formula ##STR13##
The antibiotic BMY-28121B of the formula ##STR14##
A method for therapeutically treating an animal host affected by a bacterial infection, which comprises administering to said host an effective antibacterial dose of BMY-28121A.
A method for therapeutically treating an animal host affected by a bacterial infection, which comprises administering to said host an effective antibacterial dose of BMY-28121B.
A method for therapeutically treating an animal host affected by a malignant tumor sensitive to BMY-28121A, which comprises administering to said host a tumor-inhibiting dose of BMY-28121A.
A method for therapeutically treating an animal host affected by a malignant tumor sensitive to BMY-28121B, which comprises administering to said host a tumor-inhibiting dose of BMY-28121B.
A pharmaceutical composition for treatment of bacterial infections comprising an effective antibacterial amount of BMY-28121A in combination with a pharmaceutical carrier or diluent.
A pharmaceutical composition for treatment of bacterial infections comprising an effective antibacterial amount of BMY-28121B in combination with a pharmaceutical carrier or diluent.
A pharmaceutical composition for treatment of malignant tumors in mammalian hosts comprising an effective tumor-inhibiting amount of BMY-28121A in combination with a pharmaceutical carrier or diluent.
A pharmaceutical composition for treatment of malignant tumors in mammalian hosts comprising an effective tumor-inhibiting amount of BMY-28121B in combination with a pharmaceutical carrier or diluent.
Dependencies are inferred from the claim text.